Progress of ixazomib in treatment of multiple myeloma / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells. Beginning with the use of proteasome inhibitor (PI), the treatment of MM has been significantly improved. Ixazomib is a new generation of PI, the clinical studies have shown that it has good efficacy and safety in frontline therapy, maintenance therapy and treatment of relapsed/refractory MM patients, mainly reflected in prolonging progression-free survival, low peripheral neurotoxicity and long-term medication without accumulated toxicity. This article reviews the mechanism of action, pharmacokinetics, clinical studies and adverse reactions of ixazomib, in order to provide references for the treatment of MM.